HCM News and Press, HUTCHMED (China) Limited From 08/20/23

— Randomized, double-blind, controlled trial met primary endpoint of durable response rate and all secondary endpoints — — Overall safety consistent with sovleplenib known profile — — Plans for regulatory submission underway in China,...

2023-08-11 17:59:00 ET Summary Hutchmed (China) Limited, a Chinese biopharma company, has experienced fluctuations in its stock price but has potential for improvement. The company acts as a liaison between the healthcare systems of China and the U.S., working to get its products ...

2023-08-07 13:28:03 ET Gainers: Nektar Therapeutics ( NKTR ) +87% . Enveric Biosciences ( ENVB ) +47% . Sequans Communications S.A. ( SQNS ) +31% . Tabula Rasa HealthCare ( TRHC ) +31% . Missfresh Limited ( MF ) +29% . Sovos ...

2023-08-07 10:15:28 ET Gainers: Poseida Therapeutics ( PSTX ) +33% . Tabula Rasa HealthCare ( TRHC ) +32% . Mallinckrodt plc ( MNK ) +17% . Assertio Holdings ( ASRT ) +18% . Palatin Technologies ( PTN ) +16% . Losers: Sag...

2023-08-02 17:57:42 ET TriNet Group Inc ( NYSE: TNET ) on Wednesday announced it has priced $400M in aggregate principal amount of its 7.125% senior notes due 2031 in a private offering. TriNet also expects to enter into an amendment to its revolving credit facility that would...

2023-07-31 12:33:09 ET HUTCHMED (China) Limited (HCM) Q2 2023 Earnings Conference Call July 31, 2023, 08:00 ET Company Participants Mark Lee - SVP, Corporate Finance & Development Wei-Guo Su - CEO, Chief Scientific Officer & Executive Director Johnny Chen...

2023-07-31 07:49:46 ET Hutchison China MediTech press release ( NASDAQ: HCM ): 1H Non-GAAP EPS of $0.97. Revenue of $532.9M (+163.8% Y/Y). Revenue grew 164% (173% CER) to US$533 million, with net income to HUTCHMED ( HCM ) of US$169 million (which include US$259 mi...

Strong execution on strategic direction, delivering near-term value while charting a path for growth, exemplified by global partnership with Takeda Revenue grew 164% (173% CER) to US$533 million, with net income to HUTCHMED of US$169 million (which include US$259 million of the upfro...

HONG KONG and SHANGHAI, China and FLORHAM PARK, N.J., July 20, 2023 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“ HUTCHMED ”) (Nasdaq/AIM:​HCM; HKEX:​13) today announces that the Center for Drug Evaluation of China’s National Medical Products Administratio...

HONG KONG and SHANGHAI, China and FLORHAM PARK, N.J., July 13, 2023 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“ HUTCHMED ” or the “Company”) (Nasdaq/AIM:​HCM, HKEX:​13) today announces that with effect from July 13, 2023: (i)   ...